BBIO shows dramatic balance sheet deterioration with total debt surging over 2,000% to $2.0B while stockholders' equity deficit expanded 42% to -$2.1B, despite strong revenue growth.
The massive debt increase of over $1.9B combined with widening losses and declining cash position raises serious questions about financial sustainability and potential dilution risk for shareholders. While revenue more than doubled, the company's capital structure has become significantly more leveraged and risky.
BBIO demonstrated strong commercial momentum with revenue doubling to $502.1M and accounts receivable surging nearly 3,000%, indicating rapid business growth likely from their approved products Attruby/Beyonttra. However, the financial foundation deteriorated dramatically as total debt exploded from $94M to $2.0B, stockholders' equity deficit widened to -$2.1B, and net losses expanded 35% to -$725M despite improving operating cash flow. The combination of massive new debt burden, declining cash reserves, and persistent large losses creates a precarious financial situation that overshadows the positive revenue trajectory.
Receivables surged 2853.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Debt increased 2038.2% — substantial leverage increase; assess whether deployed for growth or covering losses.
Strong top-line growth of 126.3% — accelerating demand or successful expansion into new markets.
Current liabilities surged 86.5% — significant near-term obligations; verify ability to meet short-term debt.
SG&A up 83.9% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Net income declined 35.3% — review whether driven by operations, interest costs, or non-recurring items.
Liabilities increased 26.7% — monitor debt-to-equity ratio and interest coverage.
Cash decreased 16.3% — monitor burn rate and upcoming capital needs.
Operating cash flow grew 14.4% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →